The products supplied by Special Products Limited are unlicensed medicines and defined as ‘special medicinal product’ in the Human Medicines Regulations 2012 (SI 2012/1916) as amended by the Human Medicines (Amendment) Regulation 2013 (SI 2013/1855). All products are supplied in accordance with prevailing MHRA guidance and each formulation is contracted out to an appropriate manufacturer with a UK Manufacturer’s ‘Specials’ Licence (MS).
Each medicine is backed by validated and extended shelf life, a batch number, a Certificate of Analysis and is labelled in accordance with the British Pharmacopoeia monograph on unlicensed medicines (Supplementary Chapter V). Each product is manufactured in compliance with the European Commission’s “Notes for guidance on minimizing the risk of transmitting animal spongiform encephalopathy agents via medicinal products” and any subsequent updates.
Special Products Limited operates and continually seeks to improve an effective and efficient Quality Management System, which encompasses the fundamental and general requirements of Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP). In doing so, Special Products Limited is able to ensure that it can continue to provide quality pharmaceutical products which meet both regulatory and customer requirements.
The highest ethical and quality standards are maintained by Special Products Limited which enables us to continue to fulfil the special clinical needs of patient groups. Special Products Limited is committed to the development, manufacture (via approved manufacturers) and supply of quality medicinal products in order to meet current unmet clinical needs of patients.
To read Special Products Limited’s Quality Policy, please click here.